Skip to main content

Silver-Loaded Biomimetic Hydroxyapatite Grafted Poly(ε-caprolactone) Composite Nanofibers: A Cytotoxicity Study

Buy Article:

$107.14 + tax (Refund Policy)

We report on poly(ε-caprolactone) (PCL) containing biomimetic hydroxyapatite (HA) and hydroxyapatite-silver (HA-Ag) composite nanofibers prepared via an electrospinning process for the biomedical applications. The morphology, structure and thermal properties of the PCL, PCL/HA and PCL/HA-Ag composite nanofibers were characterized by scanning electron microscopy (SEM), transmission electron microscopy (TEM), energy dispersive X-ray (EDX) spectroscopy, X-ray diffraction (XRD) and thermogravimetry (TGA). SEM images revealed that the nanofibers were well-oriented and incorporated the HA-Ag nanoparticles well. The adhesion, viability and proliferation properties of composite nanofibers and differentiation of osteoblast were carried out to study the in vitro cell compatibility of the PCL/HA/HA-Ag composite nanofibers. Our results showed that pristine PCL and PCL/HA composite nanofibers scaffold can be utilized for the bone regeneration applications, however, PCL/HA-Ag composite nanofibers results in mild cytotoxic effect to human cells.

Keywords: BIOMIMETIC HYDROXYAPATITE; CELL CULTURE; COMPOSITE NANOFIBERS; CYTOTOXICITY; ELECTROSPINNING; PCL; SILVER NANOPARTICLES

Document Type: Research Article

Publication date: 01 February 2012

More about this publication?
  • Journal of Biomedical Nanotechnology (JBN) is a peer-reviewed multidisciplinary journal providing broad coverage in all research areas focused on the applications of nanotechnology in medicine, drug delivery systems, infectious disease, biomedical sciences, biotechnology, and all other related fields of life sciences.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content